BridgeBio Pharma BBIO Reportable Segment — Gain (Loss) on Extinguishment of Debt
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's reportable segment — gain (loss) on extinguishment of debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's reportable segment — gain (loss) on extinguishment of debt?
- BridgeBio Pharma (BBIO) reported reportable segment — gain (loss) on extinguishment of debt of $0 in Q1 2026.
- How has BridgeBio Pharma's reportable segment — gain (loss) on extinguishment of debt changed year-over-year?
- BridgeBio Pharma's reportable segment — gain (loss) on extinguishment of debt increased by 100.0% year-over-year, from -$21.16M to $0.
- What does reportable segment — gain (loss) on extinguishment of debt mean?
- The financial gain or loss resulting from paying off debt earlier than its original due date.
- How do you interpret reportable segment — gain (loss) on extinguishment of debt?
- A gain indicates favorable refinancing or market conditions, while a loss reflects the cost of retiring debt early, often to reduce future interest burdens.
- How does reportable segment — gain (loss) on extinguishment of debt compare across companies?
- Common in biotech firms undergoing frequent capital restructuring or debt refinancing to manage liquidity.